New York, January 20, 2026, 14:21 EST — Regular session ongoing.
- Boston Scientific shares climbed roughly 3% in afternoon trading.
- The company highlighted new long-term data set for presentation at this week’s NANS neuromodulation meeting in Las Vegas.
- Investors remain focused on developments around a high-risk FDA early alert involving specific AXIOS stents, alongside news about the company’s upcoming Penumbra acquisition.
Shares of Boston Scientific Corp climbed roughly 3.1% to $90.77 on Tuesday, clawing back some of last week’s losses. Investors digested new clinical data amid ongoing concerns over regulatory issues and deal rumors.
This shift is significant since BSX is back to being a “show me” stock. Traders are sorting out what’s sustainable — like procedure-driven demand and fresh data — versus noise, such as occasional device safety recalls and the expenses tied to larger acquisitions.
It comes right before a hectic period. Boston Scientific is gearing up for a major scientific meeting this week, with quarterly results due in early February—two key events that could shift sentiment fast.
On Tuesday, the company announced it will showcase several long-term results from its neuromodulation portfolio at the North American Neuromodulation Society annual meeting, scheduled for Jan. 22-25. It spotlighted three-year data from its Fast-Acting Sub-perception Therapy (FAST) program alongside long-term registry outcomes involving over 500 patients. Jim Cassidy, president of neuromodulation, stated these findings “underscore our category leadership in the pain space.” Boston Scientific
Spinal cord stimulation (SCS) involves an implanted device that sends electrical pulses to dull chronic pain signals. Boston Scientific also announced plans to present an accessory for its Intracept system, which targets a particular type of low back pain associated with vertebral endplates, at the upcoming meeting.
Still, the big investor chatter focused on capital allocation. Last week, Boston Scientific struck a $14.5 billion deal to acquire Penumbra, shelling out $374 a share. The payment breaks down to roughly 73% cash and 27% stock, according to Reuters. Boston Scientific’s shares dropped about 4% the day the announcement came out.
Boston Scientific CEO Mike Mahoney told investors last week the deal could “become much stronger” and now expects it to close more likely in the second half of 2026, according to MedTech Dive. The report also noted some analysts see limited product overlap—a key factor if regulators scrutinize large medtech mergers more closely—and highlighted stiff competition in vascular and neurovascular devices, where Abbott, Medtronic, and Stryker already have strong positions. MedTech Dive
The risk tape keeps running. On Jan. 16, the U.S. Food and Drug Administration issued an early alert noting that Boston Scientific had instructed customers to pull certain AXIOS stents and electrocautery-enhanced delivery systems from use or sale. The move follows increased reports of deployment and expansion failures. As of Dec. 23, Boston Scientific had logged 167 serious injuries and three deaths linked to the problem, according to the FDA.
Investors are watching to see if the alert remains contained within narrowly scoped products with limited fallout, or if it starts to impact sales, trigger increased scrutiny, or divert management’s focus amid efforts to integrate a major acquisition.
Boston Scientific is set to report its fourth-quarter results on Feb. 4. Investors will be watching closely for guidance updates, any remarks on Penumbra’s financing and timing, and comments on device safety—factors poised to shape the next move in BSX shares.
